| Date | Upside/Downside | Analyst Firm | Price Target Change | Rating Change | Previous / Current Rating |
|---|---|---|---|---|---|
| 12/21/2022 | 664.33% | BTIG | $6 → $3 | Maintains | Buy |
| 08/25/2022 | 409.55% | Goldman Sachs | → $2 | Downgrades | Buy → Neutral |
| 05/24/2022 | 409.55% | Goldman Sachs | $3 → $2 | Maintains | Buy |
| 04/18/2022 | 1428.66% | BTIG | $10 → $6 | Maintains | Buy |
| 04/18/2022 | 1938.22% | Mizuho | $17 → $8 | Maintains | Buy |
| 01/24/2022 | 1428.66% | B. Riley Securities | $13 → $6 | Maintains | Buy |
| 01/06/2022 | 1938.22% | Goldman Sachs | $7 → $8 | Upgrades | Neutral → Buy |
| 08/03/2021 | 1683.44% | JP Morgan | $16 → $7 | Downgrades | Overweight → Neutral |
| 06/29/2021 | 4995.54% | Cantor Fitzgerald | → $20 | Initiates Coverage On | → Overweight |
| 06/15/2021 | 4995.54% | BTIG | → $20 | Initiates Coverage On | → Buy |
| 05/18/2021 | 5250.32% | B. Riley Securities | → $21 | Initiates Coverage On | → Buy |
| 01/07/2021 | 3976.43% | Mizuho | → $16 | Initiates Coverage On | → Buy |
| 06/08/2020 | 3721.66% | Goldman Sachs | → $15 | Upgrades | Neutral → Buy |
| 12/06/2019 | — | BTIG | Initiates Coverage On | → Buy | |
| 12/06/2019 | 4485.99% | Goldman Sachs | → $18 | Assumes | → Neutral |
| 03/25/2019 | 3976.43% | Goldman Sachs | $17 → $16 | Downgrades | Buy → Neutral |
| 03/15/2019 | — | Raymond James | Initiates Coverage On | → Outperform | |
| 07/16/2018 | 4485.99% | Goldman Sachs | → $18 | Initiates Coverage On | → Buy |
| 07/16/2018 | 4485.99% | JP Morgan | → $18 | Initiates Coverage On | → Overweight |
| 07/16/2018 | — | Cowen & Co. | Initiates Coverage On | → Outperform | |
| 07/16/2018 | 5505.1% | Wedbush | → $22 | Initiates Coverage On | → Outperform |
What is the target price for Magenta Therapeutics (MGTA)?
The latest price target for Magenta Therapeutics (NASDAQ: MGTA) was reported by BTIG on December 21, 2022. The analyst firm set a price target for $3.00 expecting MGTA to rise to within 12 months (a possible 664.33% upside). 7 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for Magenta Therapeutics (MGTA)?
The latest analyst rating for Magenta Therapeutics (NASDAQ: MGTA) was provided by BTIG, and Magenta Therapeutics maintained their buy rating.
When is the next analyst rating going to be posted or updated for Magenta Therapeutics (MGTA)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Magenta Therapeutics, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Magenta Therapeutics was filed on December 21, 2022 so you should expect the next rating to be made available sometime around December 21, 2023.
Is the Analyst Rating Magenta Therapeutics (MGTA) correct?
While ratings are subjective and will change, the latest Magenta Therapeutics (MGTA) rating was a maintained with a price target of $6.00 to $3.00. The current price Magenta Therapeutics (MGTA) is trading at is $0.39, which is out of the analyst's predicted range.